Norveška - norveščina - Statens legemiddelverk

dechra veterinary product a/s - medroksyprogesteronacetat - tablett - 5 mg

Norveška - norveščina - Statens legemiddelverk

ecuphar veterinaria s.l.u. - suksibuzon - granulat - 1.5 g/10 g

Norveška - norveščina - Statens legemiddelverk

ecuphar veterinaria s.l.u. - etamsylat - injeksjonsvæske, oppløsning - 125 mg/ ml

Norveška - norveščina - Statens legemiddelverk

floris veterinaire produkten bv - acepromazinmaleat - oralgel - 35 mg/ ml

Norveška - norveščina - Statens legemiddelverk

dechra veterinary products (1) - klindamycinhydroklorid - tyggetablett - 440 mg

Norveška - norveščina - Statens legemiddelverk

dechra veterinary products (1) - klindamycinhydroklorid - tyggetablett - 55 mg

Norveška - norveščina - Statens legemiddelverk

dechra veterinary products (1) - klindamycinhydroklorid - tyggetablett - 220 mg

Evropska unija - norveščina - EMA (European Medicines Agency)

nova laboratories ireland limited - 6-merkaptopurinmonohydrat - leukemi, lymfoid - antineoplastiske midler - xaluprine er indisert for behandling av akutt lymfoblastisk leukemi (all) hos voksne, ungdom og barn.

Evropska unija - norveščina - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graft-avvisning - immunsuppressive - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Evropska unija - norveščina - EMA (European Medicines Agency)

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - immune sera og immunglobuliner, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.